Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration

Kidney International

Volumn 67, Issue 3, 2005, Pages 1062-1069

  Lacour, Bernard ^a   Lucas, Anthony ^b   Auchère, Daniel ^b   Ruellan, Nadya ^b   De Serre Patey, Natalie Mariaud ^b   Drüeke, Tilman B ^b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE

Author keywords

Chronic renal failure; Lanthanum; Oral overload; Tissue concentration; Uremia

Indexed keywords

LANTHANUM CARBONATE; LANTHANUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TISSUE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EXCRETION; HEART MUSCLE; KIDNEY; KIDNEY MASS; LIVER WEIGHT; LUNG PARENCHYMA; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; SKELETAL MUSCLE; ANIMAL; BODY WEIGHT; METABOLISM; ORAL DRUG ADMINISTRATION; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; SMALL INTESTINE; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; INTESTINE, SMALL; KIDNEY; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 20844444775     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00171.x     Document Type: Article

References (14)

1. NATIONAL KIDNEY FOUNDATION: K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(Suppl 3):S1-S70, 2003
2. CHERTOW GM, RAGGI P, CHASAN-TABER S, et al: Determinants of progressive vascular calcification in haemodialysis patients. Nephrol Dial Transplant 19:1489-1496, 2004
3. LONDON GM, GUERIN AP, MARCHAIS SJ, et al: Arterial media calcification in end-stage renal disease: Impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740, 2003
4. GOODMAN WG, GOLDIN J, KUIZON BD, et al: Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478-1483, 2000
5. MERJANIAN R, BUDOFF M, ADLER S, et al: Coronary artery, aortic wall, and valvular calcification in nodialysed individuals with type 2 diabetes and renal disease. Kidney Int 64:263-271, 2003
6. LESKINEN Y, SALENIUS JP, LEHTIMAKI T, et al: The prevalence of peripheral arterial disease and medial arterial calcification in patients with chronic renal failure: requirements for diagnostics. Am J Kidney Dis 40:472-479, 2002
7. ROSOFF B, SIEGEL E, WILLIAMS L, SPENCER H: Distribution and excretion of radioactive rare-earth compounds in mice. Int J Appl Rad Isotopes 14:129-135, 1963
8. D'HAESE P, SPASOVSKI GB, SIKOLE A, et al: A multicenter study on the effects of lanthanum carbonate (Fosrenol™) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 63:S73-S78, 2003
9. YOKOZAWA T, ZHENG PD, OURA H, KOIZUMI F: Animal model of adenine-induced chronic renal failure in rats. Nephron 44:230-234, 1986
10. TERZI F, BEAUFILS H, LAOUARI D, et al: Renal effect of antihypertensive drugs depends on sodium diet in the excision remnant kidney model. Kidney Int 42:354-363, 1992
11. ITTEL TH, BUDDINGTON B, MILLER NL, ALFREY AC: Enhanced gastrointestinal absorption of aluminum in the uremic state. Kidney Int 32:821-826, 1987
12. ITTEL TH, KLUGE R, SIEBERTH HG: Enhanced gastrointestinal absorption of aluminium in uraemia: Time course and effect of vitamin D. Nephrol Dial Transplant 3:617-623, 1988
13. FULTON B, JEFFERY EH: Absorption and retention of aluminum from drinking water 1. Effect of citric and ascorbic acids on aluminum tissue levels in rabbits. Fund Appl Toxicol 14:788-796, 1990
14. YOKEL RA, RHINEHEIMER SS, BRAUER RD, et al: Aluminum bioavailability from drinking water is very low and is not appreciably influenced by stomach contents or water hardness. Toxicology 161:93-101, 2001